Trial Profile
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2022
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 01 Dec 2021 Results published in the Leukemia Research
- 20 Apr 2018 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology